Close Menu

antibodies

The companies will combine marketing efforts for their antibodies and proteomics assays.

The company aims to tackle the two major issues in the antibody field — poor quality and too few antibodies — by defining a so-called "affome," an antibody set against all proteins in the human proteome.

Citing the FDA's handling of KRAS testing for anti-EGFR monoclonal antibodies, the report asserts that in the near term complex genetic tests such as Oncotype DX should be "performed through CLIA labs, and not held up by slow regulatory processes."

Several of the company's microarray-based tests have been certified in China and Europe.

Regeneron Inks mAb Pact with UT-Southwestern; Mount Sinai taps DiscoveryBioMed for bioassay services; Repligen licenses bipolar disorder Rx from Harvard's McLean, and more …

As part of the deal, Merck will pay Xencor a $3 million upfront license fee, make an additional payment if it selects an Xtend variant, and pay clinical development milestones and royalties on product sales.

Genomics vs. Cancer

Premium

Recent advances in the battle against cancer have come from sequencing, microRNAs, barcode arrays, disease stratification, pathway analysis, and more.

NKT licensed the IP from Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, and Massachusetts General Hospital. As a result, each of the Harvard Med-affiliated institutes has been awarded an undisclosed equity stake in the company.

The decision, part of the state's 2010 budget, will allow life-sci shops in FY2011 to determine the percentage of corporate income taxes they owe the state based solely on sales, rather than combining sales with payroll and owned property.

Industry Briefs : Mar 12, 2009

Premium

Gentel, Eprogen, Novozymes, Proteome Sciences, Pepsca, Advanced Proteome Therapeutics, AnaSpec

Pages

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.